Comparing the current results to its competitors, Lumos Pharma Inc reported Revenue increase in the 3 quarter 2024 by 10271.43 % year on year. The sales growth was above Lumos Pharma Inc 's competitors' average revenue growth of 8.71 %, achieved in the same quarter.
Lumos Pharma Inc , slower than the average decrease reported by the company's competitors of -15.9 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -15.9 %
Lumos Pharma Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment for the development and commercialization of new therapeutic products, including LUM-201. Competitors include major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology firms worldwide. Several large pharmaceutical and biotechnology companies, such as Eli Lilly and Company and Novo Nordisk (including Novo Nordisk A/S), currently market and sell recombinant human growth hormone (rhGH) therapies to the target patient group. These competitors have established experience in the relevant indications. Additional potential competitors include academic institutions, government agencies, and other public and private research organizations.
The current standard of care for growth therapies in the United States involves daily subcutaneous injections of rhGH, with marketed therapies including Norditropin®, Humatrope®, and Nutropin-A. Competition also exists from manufacturers and sellers of the LUM-201 compound who may distribute it illegally or for unapproved indications. Furthermore, generic competitors may enter the market following the expiration of data exclusivity periods, particularly in the European Union, where a regulatory process exists to authorize generic versions of innovative drugs.
September 25, 2024
Lumos Pharma Enhances Pediatric Growth Hormone Deficiency Research: Presentation at APPES 2024 Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical organization dedicated to addressing therapeutics for rare diseases, has announced a significant milestone in its research efforts. The company recently revealed that its updated analysis from the Phase 2 OraGrowtH210 clinical trial has been accepted for an oral presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society (APPES 2024). This prestigious conference will take place from October 2-5, 2024, in New Delhi, India.The focus of the presentation will be on the efficacy and safety of LUM-201, an oral th...
June 4, 2024
Lumos Pharma, a clinical-stage biopharmaceutical company specializing in rare disease therapeutics, has revealed fresh analyses of data from its Phase 2 OraGrowtH212 clinical trial. The findings were presented at the 2024 Annual Meeting of the Endocrine Society (ENDO) held in Boston from June 1-4, 2024. This article examines the key details and implications of Lumos Pharma s new analyses, highlighting their significance in advancing treatment options for rare diseases.Summary of the Phase 2 OraGrowtH212 Trial:The Phase 2 OraGrowtH212 clinical trial conducted by Lumos Pharma aimed to evaluate the effectiveness of a therapeutic intervention in addressing rare diseases. While specific details of the trial were ...
Ligand Pharmaceuticals Inc operates on a business model focused on discovering and acquiring new drugs and technologies to license them to pharmaceutical companies. They generate revenue through licensing fees, milestone payments, and royalties from the sales of their partnered products. Their approach allows them to leverage their expertise and resources while minimizing risk, ultimately leading to long-term value creation for their shareholders.
Enliven Therapeutics Inc's business model focuses on developing and providing effective therapeutic solutions that enhance patient wellness and quality of life.
Sources:
Lumos Pharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Lumos Pharma Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
